B Desoize

Summary

Country: France

Publications

  1. ncbi Cell culture as spheroids: an approach to multicellular resistance
    B Desoize
    Laboratoire de Biochimie, IFR53 Biomolecules, Faculte de Pharmacie, Reims, France
    Anticancer Res 18:4147-58. 1998
  2. ncbi Puzzles in the clinical pharmacokinetics of fluorouracil
    B Desoize
    IFR53 EA2063, Laboratoire de Biochimie, Reims, France
    Anticancer Res 18:4607-10. 1998
  3. ncbi Multicellular resistance: a paradigm for clinical resistance?
    B Desoize
    Laboratoire de Biochimie et de Biologie Moleculaire, Faculte de Pharmacie, IFR 51, EA 2063, Reims, France
    Crit Rev Oncol Hematol 36:193-207. 2000
  4. ncbi Metals and metal compounds in cancer treatment
    Bernard Desoize
    Laboratoire de Biochimie et de Biologie Moleculaire, EA 3306, IFR 53, Faculte de Pharmacie, 51 rue Cognacq Jay, 51096 Reims Cedex, France
    Anticancer Res 24:1529-44. 2004
  5. ncbi Metals and metal compounds in carcinogenesis
    Bernard Desoize
    Laboratoire de Biochimie et de Biologie Moleculaire, Faculte de Pharmacie, 51 Rue Cognac Jay, IFR 53, EA 3306, 51096 Reims, France
    In Vivo 17:529-39. 2003
  6. ncbi Particular aspects of platinum compounds used at present in cancer treatment
    Bernard Desoize
    Laboratoire de Biochimie et de Biologie Moleculaire, EA 3306, Faculte de Pharmacie, IFR 53, 51 rue Cognacq Jay, Reims, France
    Crit Rev Oncol Hematol 42:317-25. 2002
  7. ncbi Gallium in cancer treatment
    Philippe Collery
    Service de cancérologie, Polyclinique Maymard, rue Marcel Paul, Bastia, France
    Crit Rev Oncol Hematol 42:283-96. 2002
  8. ncbi Cancer and metals and metal compounds: part II--cancer treatment
    Bernard Desoize
    Crit Rev Oncol Hematol 42:213-5. 2002
  9. ncbi Cancer and metals and metal compounds: part I--carcinogenesis
    Bernard Desoize
    Crit Rev Oncol Hematol 42:1-3. 2002
  10. ncbi Stromal reaction and tumour growth
    Bernard Desoize
    Crit Rev Oncol Hematol 49:173-6. 2004

Collaborators

  • O Bouche
  • Philippe Collery
  • Claudie Madoulet
  • Bernhard Keppler

Detail Information

Publications13

  1. ncbi Cell culture as spheroids: an approach to multicellular resistance
    B Desoize
    Laboratoire de Biochimie, IFR53 Biomolecules, Faculte de Pharmacie, Reims, France
    Anticancer Res 18:4147-58. 1998
    ..The mechanism of action of this new pharmacological class is the disruption of the cell adhesion forces...
  2. ncbi Puzzles in the clinical pharmacokinetics of fluorouracil
    B Desoize
    IFR53 EA2063, Laboratoire de Biochimie, Reims, France
    Anticancer Res 18:4607-10. 1998
    ....
  3. ncbi Multicellular resistance: a paradigm for clinical resistance?
    B Desoize
    Laboratoire de Biochimie et de Biologie Moleculaire, Faculte de Pharmacie, IFR 51, EA 2063, Reims, France
    Crit Rev Oncol Hematol 36:193-207. 2000
    ..The explanation given is that it improves drug penetration into spheroids. We now hypothesise that hyaluronidase, in fact, decreases MCR and thus could be the first member of a new therapeutic class...
  4. ncbi Metals and metal compounds in cancer treatment
    Bernard Desoize
    Laboratoire de Biochimie et de Biologie Moleculaire, EA 3306, IFR 53, Faculte de Pharmacie, 51 rue Cognacq Jay, 51096 Reims Cedex, France
    Anticancer Res 24:1529-44. 2004
    ..The last metal reviewed, platinum, has given some of the very best anti-cancer drugs. Four derivatives are used today in the clinic; their mechanism of action and of resistance are described...
  5. ncbi Metals and metal compounds in carcinogenesis
    Bernard Desoize
    Laboratoire de Biochimie et de Biologie Moleculaire, Faculte de Pharmacie, 51 Rue Cognac Jay, IFR 53, EA 3306, 51096 Reims, France
    In Vivo 17:529-39. 2003
    ..Magnesium deficiency and iron excess are not exactly carcinogenetic, but certain concentrations of these metal ions are needed to prevent cancer...
  6. ncbi Particular aspects of platinum compounds used at present in cancer treatment
    Bernard Desoize
    Laboratoire de Biochimie et de Biologie Moleculaire, EA 3306, Faculte de Pharmacie, IFR 53, 51 rue Cognacq Jay, Reims, France
    Crit Rev Oncol Hematol 42:317-25. 2002
    ..Oxaliplatin give interesting results in a number of cancers. The official recommendation in Japan for nedaplatin is head and neck, testicular, lung, oesophageal, ovarian, and cervical cancer...
  7. ncbi Gallium in cancer treatment
    Philippe Collery
    Service de cancérologie, Polyclinique Maymard, rue Marcel Paul, Bastia, France
    Crit Rev Oncol Hematol 42:283-96. 2002
    ..Although not as potent as platinum in vitro, the anticancer activity of Ga should not be ignored, but the schedule of administration still needs to be optimised and new compounds are now under clinical investigations...
  8. ncbi Cancer and metals and metal compounds: part II--cancer treatment
    Bernard Desoize
    Crit Rev Oncol Hematol 42:213-5. 2002
  9. ncbi Cancer and metals and metal compounds: part I--carcinogenesis
    Bernard Desoize
    Crit Rev Oncol Hematol 42:1-3. 2002
  10. ncbi Stromal reaction and tumour growth
    Bernard Desoize
    Crit Rev Oncol Hematol 49:173-6. 2004
  11. ncbi Immunosuppressive agents are also carcinogens
    Bernard Desoize
    Crit Rev Oncol Hematol 56:1-4. 2005
  12. ncbi "Antibodies in cancer treatment"
    Bernard Desoize
    Crit Rev Oncol Hematol 62:23-5. 2007
  13. ncbi Imaging and cancer--I
    Bernard Desoize
    Crit Rev Oncol Hematol 68:37-8. 2008